Bio Green Med Solution, Inc. — fact timeline

Bio Green Med Solution, Inc. reported the year ended December 31, 2023 results: net income $22.6 million.

“Net loss for the three months and year ended December 31, 2023, was $5.3 million and $22.6 million”

Bio Green Med Solution, Inc. reported the three months ended December 31, 2023 results: net income $5.3 million.

“Net loss for the three months and year ended December 31, 2023, was $5.3 million”

Mark H. Kirschbaum departed as Chief Medical Officer at Bio Green Med Solution, Inc..

“the employment of Mark H. Kirschbaum, M.D. as Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. (the “Company”) was terminated by the Company, effective immediately”

Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain of our executive officers (effective 2023-12-21).

“On December 21, 2023, in a separate concurrent insider private placement (the "Insider Private Placement"), we also entered into a Securities Purchase Agreement with certain of our executive officers (the "Insider Securities Purchase Agreement")”

Bio Green Med Solution, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (the "Placement Agent") (effective 2023-12-21).

“Ladenburg Thalmann & Co. Inc. (the "Placement Agent") acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the "Placement Agency Agreement"), dated December 21, 2023, by and between the Company and the Placement Agent.”

Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain institutional investors ("Purchasers") valued at approximately $1.29 million (effective 2023-12-21).

“On December 21, 2023, Cyclacel Pharmaceuticals, Inc. (the "Company," "we" or "us") entered into a securities purchase agreement ("Securities Purchase Agreement") with certain institutional investors ("Purchasers").”

Bio Green Med Solution, Inc. shareholders approved The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1. at the 2023-12-08 meeting.

“Proposal 2 The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.”

Bio Green Med Solution, Inc. shareholders approved The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-15, with the exact ratio to be set within that range at the discretion of th at the 2023-12-08 meeting.

“Item 5.07. Submission of Matters to a Vote of Security Holders. Cyclacel Pharmaceuticals, Inc. (the “Company”) held a Special Meeting on December 8, 2023 at 9:30 a.m. Eastern Time in virtual format. Of the Company’s 12,642,822 shares of common stock issued and outstanding and eligible to vote as of the record date of November 6, 2023, 7,315,280 shares, or approximately 57.86% of the eligible shares of common stock, were present virtually or represented by proxy. A quorum was present for all matters. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 14, 2023. The following actions were taken at the Special Meeting: Proposal 1 The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-15, with the exact ratio to”

Bio Green Med Solution, Inc. received a nasdaq noncompliance notice notice regarding late filing.

“November 21, 2023, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s continued listing standards because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”). Under Nasdaq rules, the Company now has 60 calendar days (or until January 20, 2024) to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar da”

Bio Green Med Solution, Inc. reported that prior financial statements should not be relied upon.

“Restatement of Historical Financial Results On November 14, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Cyclacel Pharmaceuticals, Inc. (the “Company”), based, in part, on the recommendation of, and after consultation with, the Company’s management concluded that the Company’s previously issued audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the years ended December 31, 2022 and 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), and the Company’s unaudited consolidated financial statements included in the Quarterly Reports on Form 10-Q for September 30, 2021 and the quarterly 2022 fiscal year periods (the “Historical Quarterly Reports”) as well as the unaudited consolidated financial statements included in the Company’s Quarterly Reports on”

Bio Green Med Solution, Inc. reported third quarter ended September 30, 2023 results: net income $6.1 million.

“Net loss for the three months ended September 30, 2023, was $6.1 million, compared to $5.1 million for the same period in 2022.”

Bio Green Med Solution, Inc. reported financial results for six months ended June 30, 2023.

“Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.”

Bio Green Med Solution, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $5.4 million.

“Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.”

Bio Green Med Solution, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“July 5, 2023, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, or until January 2, 2024 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “”

Bio Green Med Solution, Inc. shareholders approved Election of Dr. Samuel L. Barker as a Class 2 director by holders of Preferred Stock.

“Votes of the preferred stockholders regarding the election of Dr. Samuel L. Barker as a Class 2 director were as follows:”

Bio Green Med Solution, Inc. shareholders approved Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.

“Votes of the common stockholders, on an advisory basis, regarding the executive compensation of the Company's named executive officers, as disclosed in the Company's proxy statement, were as follows:”

Bio Green Med Solution, Inc. shareholders approved Approval of an amendment to the Company's 2018 Equity Incentive Plan.

“Votes of the common stockholders regarding the approval of an amendment to the Company's 2018 Equity Incentive Plan were as follows:”

Bio Green Med Solution, Inc. shareholders approved Ratification of the selection of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-12-31 meeting.

“Votes of the common stockholders regarding the ratification of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 were as follows:”

Bio Green Med Solution, Inc. shareholders approved Re-election of two Class 2 directors to the Company's board of directors.

“Votes of the common stockholders regarding the election of the Class 2 director nominees were as follows:”

Bio Green Med Solution, Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $5.8 million.

“Net loss for the three months ended March 31, 2023, was $5.8 million, compared to $4.1 million for the same period in 2022.”

Bio Green Med Solution, Inc. reported the year ended December 31, 2022 results: net income $21.2 million.

“Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million”

Bio Green Med Solution, Inc. reported the three months ended December 31, 2022 results: net income $7.4 million.

“Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 4, 2023, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) for the last 30 consecutive business days, the Common Stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2), initiating an automatic 180 calendar-day grace period for the Company to regain compliance. The notice has no immediate effect on the listing or trading of the Company”

Bio Green Med Solution, Inc. reported financial results for the third quarter ended September 30, 2022.

“a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “ Company ”), dated November 9, 2022, announcing certain financial results for the third quarter ended September 30, 2022.”